In one of the first Eastern District of Texas interpretations of the Hatch-Waxman Act, the federal law governing the procedure for bringing generic drugs to market, brand-name drug company Allergan Inc. has prevailed against five generic drug makers.
On Aug. 22 in Allergan Inc. v. Sandoz Inc. , U.S. District Judge T. John Ward ruled that the four Allergan patents were valid and that the four defendants in the consolidated case had infringed upon it.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
